Search Results - "Branson, Michael"

Critical aspects of the Bayesian approach to phase I cancer trials by Neuenschwander, Beat, Branson, Michael, Gsponer, Thomas

“…The Bayesian approach to finding the maximum‐tolerated dose in phase I cancer trials is discussed. The suggested approach relies on a realistic dose–toxicity…”
Get full text

A note on the power prior by Neuenschwander, Beat, Branson, Michael, Spiegelhalter, David J.

“…The power prior by Ibrahim and Chen (Statist. Sci. 2000; 15:46–60) is one of several methods to incorporate historical data in the analysis of a clinical…”
Get full text

Summarizing historical information on controls in clinical trials by Neuenschwander, Beat, Capkun-Niggli, Gorana, Branson, Michael, Spiegelhalter, David J

“…Background Historical information is always relevant when designing clinical trials, but it might also be incorporated in the analysis. It seems appropriate to…”
Get full text

Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation by Benda, Norbert, Branson, Michael, Maurer, Willi, Friede, Tim

“…Modern drug development requires an efficient clinical development program to have a reasonable chance of successfully leading to the submission of the…”
Get full text

Wage losses for displaced workers in the U.S.: What portion can be explained by the loss of union status? by Branson, Michael D.L

“…This paper examines the role of changes in union status in determining reemployment wages for displaced workers. The author uses a data set adapted from the…”
Get full text

Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology by Brannath, Werner, Zuber, Emmanuel, Branson, Michael, Bretz, Frank, Gallo, Paul, Posch, Martin, Racine-Poon, Amy

“…The ability to select a sensitive patient population may be crucial for the development of a targeted therapy. Identifying such a population with an acceptable…”
Get full text

A proof of concept phase II non-inferiority criterion by Neuenschwander, Beat, Rouyrre, Nicolas, Hollaender, Norbert, Zuber, Emmanuel, Branson, Michael

“…Traditional phase III non‐inferiority trials require compelling evidence that the treatment vs control effect bfθ is better than a pre‐specified…”
Get full text

Active life expectancy by Katz, S, Branch, L G, Branson, M H, Papsidero, J A, Beck, J C, Greer, D S

“…This study was designed to demonstrate the feasibility of forecasting functional health for the elderly. Using life-table techniques, we analyzed the expected…”
Get more information

The future of drug development: advancing clinical trial design by Orloff, John, Douglas, Frank, Pinheiro, Jose, Levinson, Susan, Branson, Michael, Chaturvedi, Pravin, Ette, Ene, Gallo, Paul, Hirsch, Gigi, Mehta, Cyrus, Patel, Nitin, Sabir, Sameer, Springs, Stacy, Stanski, Donald, Evers, Matthias R, Fleming, Edd, Singh, Navjot, Tramontin, Tony, Golub, Howard

“…Orloff and colleagues describe how moving from the traditional approach to clinical trials based on sequential, distinct phases towards a more integrated…”
Get full text

A combined score test for binary and ordinal endpoints from clinical trials by Whitehead, John, Branson, Michael, Todd, Susan

“…There is growing interest, especially for trials in stroke, in combining multiple endpoints in a single clinical evaluation of an experimental treatment. The…”
Get full text

Bayesian models for subgroup analysis in clinical trials by Jones, Hayley E, Ohlssen, David I, Neuenschwander, Beat, Racine, Amy, Branson, Michael

“…Background In a pharmaceutical drug development setting, possible interactions between the treatment and particular baseline clinical or demographic factors…”
Get full text

Testing and estimation in flexible group sequential designs with adaptive treatment selection by Posch, Martin, Koenig, Franz, Branson, Michael, Brannath, Werner, Dunger-Baldauf, Cornelia, Bauer, Peter

“…Integrating selection and confirmation phases into a single trial can expedite the development of new treatments and allows to use all accumulated data in the…”
Get full text

Estimating a treatment effect in survival studies in which patients switch treatment by Branson, Michael, Whitehead, John

“…For disease indications such as Acquired Immune Deficiency Syndrome (AIDS) and various cancers, randomization to a pure control treatment may be scientifically…”
Get full text

Authors' reply by Neuenschwander, Beat, Branson, Michael, Spiegelhalter, David J.

Get full text

Authors' reply by Neuenschwander, Beat, Branson, Michael, Spiegelhalter, David J.

Get full text

Authors' reply by Neuenschwander, Beat, Branson, Michael, Spiegelhalter, David J.

Get full text

A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates by Bailey, Stuart, Neuenschwander, Beat, Laird, Glen, Branson, Michael

“…A Bayesian approach to finding the maximum tolerated dose (MTD) is presented. The approach is flexible, allowing inclusion of covariates, and enables…”
Get full text

Creating a suite of macros for meta-analysis in SAS ®: A case study in collaboration by Senn, Stephen, Weir, James, Hua, Tsushung A., Berlin, Conny, Branson, Michael, Glimm, Ekkehard

“…A series of macros that have been created to perform fixed and random effects meta-analysis in SAS ® are described as is the motivation for their creation…”
Get full text

Modeling Missingness for Time-to-Event Data: A Case Study in Osteoporosis by Neuenschwander, Beat, Branson, Michael

“…Clinical trials of long duration are often hampered by high dropout rates, making statistical inference and interpretation of results difficult. Statistical…”
Get full text

Creating a suite of macros for meta-analysis in SAS®: A case study in collaboration by Berlin, Conny, Senn, Stephen, Glimm, Ekkehard, Hua, Tsushung A, Weir, James, Branson, Michael

“…A series of macros that have been created to perform fixed and random effects meta-analysis in SAS® are described as is the motivation for their creation…”
Get full text